MedTrace Logo

Chemotherapy-related Toxicity, Nutritional Status and Quality of Life

NCT02848807 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-07-29

No results posted yet for this study

Summary

Determine whether nutritional support with high protein ONS in adult oncologic patients in the first step of cancer cachexia - asymptomatic precachexia, influence on the toxicity of systemic therapy.

Conditions

Interventions

DIETARY_SUPPLEMENT

NUTRIDRINK Compact Protein

high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)

Sponsors & Collaborators

  • Nutricia Foundation

    collaborator OTHER

  • University Clinical Centre, Gdansk

    lead OTHER

Principal Investigators

  • Sylwia Malgorzewicz, MD, PhD · University Clinical Centre, Gdansk, Poland

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02848807 on ClinicalTrials.gov